

## Product Update

magnesium glycerophosphate 4mmol chewable tablet (Neomag<sup>®</sup>)

SMC No 1267/17

Neoceuticals Ltd

4 August 2017

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**magnesium glycerophosphate (Neomag<sup>®</sup>)** is accepted for use within NHS Scotland.

**Indication under review:** as an oral magnesium supplement for the treatment of patients with chronic magnesium loss or hypomagnesaemia as diagnosed by a doctor. Magnesium glycerophosphate is also indicated for adult patients with hypomagnesaemia due to the concomitant administration of loop and thiazide diuretics or other drugs which cause hypomagnesaemia.

Unlicensed tablet formulations of magnesium glycerophosphate have been used in the NHS in Scotland. This product provides a licensed preparation at a similar cost.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 07 June 2017.*

**Chairman  
Scottish Medicines Consortium**